FDA supplemental approval: Hydrocodone Bitartrate AND Acetaminophen (REMS)

AI Summary

This is an FDA supplemental approval record for a fixed-dose combination of hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg in tablet form, submitted under ANDA 040656 with REMS (Risk Evaluation and Mitigation Strategy) requirements. The record documents the regulatory action and approval date but contains no clinical trial data, efficacy results, or safety findings.

Plain-language summary

FDA supplemental approval of a hydrocodone bitartrate and acetaminophen combination tablet with REMS requirements; this is a regulatory action, not a clinical trial.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory approval does not provide clinical evidence of efficacy, safety, or comparative benefit. Clinicians should refer to the approved product labelling and REMS requirements for prescribing guidance.

Caveats

• This regulatory record does not contain or summarize clinical trial results, efficacy data, or safety findings.
• No comparator arm or control group is reported.
• REMS requirements are mentioned but not detailed in this record.
• The record is dated 2026, which is in the future; confirm current FDA status independently.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.